Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
InMed Pharmaceuticals ( (INM) ) has issued an announcement.
On February 12, 2025, InMed Pharmaceuticals reported its financial results for the second quarter of fiscal 2025, which ended on December 31, 2024. The company highlighted progress in its pharmaceutical pipeline, notably with INM-901 for Alzheimer’s disease and INM-089 for dry age-related macular degeneration. Despite a net loss of $2.6 million for the quarter, InMed’s BayMedica business unit achieved a 189% improvement in net income compared to the previous year, despite a 10% revenue decrease. The company plans to continue focusing on advancing its drug candidates while managing expenses.
More about InMed Pharmaceuticals
InMed Pharmaceuticals Inc. is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs.
YTD Price Performance: -33.33%
Average Trading Volume: 497,707
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $2.32M
For an in-depth examination of INM stock, go to TipRanks’ Stock Analysis page.
